Publicacións (107) Publicacións nas que participase algún/ha investigador/a

2021

  1. A phase 3 trial of azacitidine versus a semi-intensive fludarabine and cytarabine schedule in older patients with untreated acute myeloid leukemia

    Cancer, Vol. 127, Núm. 12, pp. 2003-2014

  2. A phase Ib, open-label, dose-escalation trial of the anti-CD37 monoclonal antibody, BI 836826, in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory diffuse large B-cell lymphoma

    Investigational New Drugs, Vol. 39, Núm. 4, pp. 1028-1035

  3. Activation-induced deaminase is critical for the establishment of DNA methylation patterns prior to the germinal center reaction

    Nucleic Acids Research, Vol. 49, Núm. 9, pp. 5057-5073

  4. Allogeneic Stem Cell Transplantation for MDS

    Hemato, Vol. 2, Núm. 3, pp. 545-555

  5. Anti-TGFβ (Transforming Growth Factor β) Therapy With Betaglycan-Derived P144 Peptide Gene Delivery Prevents the Formation of Aortic Aneurysm in a Mouse Model of Marfan Syndrome

    Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 41, Núm. 9, pp. E440-E452

  6. Association of abca4 gene polymorphisms with cleft lip with or without cleft palate in the polish population

    International Journal of Environmental Research and Public Health, Vol. 18, Núm. 21

  7. Association of calprotectin with other inflammatory parameters in the prediction of mortality for ischemic stroke

    Journal of Neuroinflammation, Vol. 18, Núm. 1

  8. Association of sdf1 and mmp12 with atherosclerosis and inflammation: Clinical and experimental study

    Life, Vol. 11, Núm. 5

  9. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

    Modern Pathology, Vol. 34, Núm. 1, pp. 59-69

  10. B-cell regeneration profile and minimal residual disease status in bone marrow of treated multiple myeloma patients

    Cancers, Vol. 13, Núm. 7

  11. Belantamab mafodotin in combination with novel agents in relapsed/refractory multiple myeloma: DREAMM-5 study design

    Future Oncology, Vol. 17, Núm. 16, pp. 1987-2003

  12. Bleeding risk in hospitalized patients with COVID-19 receiving intermediate- or therapeutic doses of thromboprophylaxis

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 8, pp. 1981-1989

  13. CD137 (4-1BB) costimulation of CD8+ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation

    Nature Communications, Vol. 12, Núm. 1

  14. CD137 Costimulation Counteracts TGFβ Inhibition of NK-cell Antitumor Function

    Cancer Immunology Research, Vol. 9, Núm. 12, pp. 1476-1490

  15. Can fibrinolytic therapy be clinically useful in severe pneumonia caused by COVID-19?

    Journal of Thrombosis and Thrombolysis, Vol. 51, Núm. 3, pp. 633-636

  16. Cereblon enhancer methylation and IMiD resistance in multiple myeloma

    Blood, Vol. 138, Núm. 18, pp. 1721-1726

  17. Characteristics of isolated superficial vein thrombosis and diagnostic-therapeutic management in spanish hospital emergency departments:The altamira study

    Emergencias, Vol. 33, Núm. 6, pp. 433-440

  18. Characterization of complete lncRNAs transcriptome reveals the functional and clinical impact of lncRNAs in multiple myeloma

    Leukemia, Vol. 35, Núm. 5, pp. 1438-1450

  19. Clinical characteristics and 3-month outcomes in cancer patients with incidental versus clinically suspected and confirmed pulmonary embolism

    European Respiratory Journal, Vol. 58, Núm. 1

  20. Comparative clinical prognosis of massive and non-massive pulmonary embolism: A registry-based cohort study

    Journal of Thrombosis and Haemostasis, Vol. 19, Núm. 2, pp. 408-416